Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free AIXC Stock Alerts

Qualigen Therapeutics (AIXC) Competitors

Qualigen Therapeutics logo
$1.30 -0.05 (-3.33%)
As of 03:15 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

AIXC vs. CRDF, TTRX, CYPH, CGTX, and ONCY

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include Cardiff Oncology (CRDF), Turn Therapeutics (TTRX), Cypherpunk Technologies (CYPH), Cognition Therapeutics (CGTX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Qualigen Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,733.22%. Cardiff Oncology's return on equity of -82.01% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-7,733.22% -82.01% -64.09%
Qualigen Therapeutics N/A -771.52%-79.52%

Qualigen Therapeutics has lower revenue, but higher earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$590K191.78-$45.85M-$0.69N/A
Qualigen TherapeuticsN/AN/A-$16.97M-$7.50N/A

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cardiff Oncology had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for Cardiff Oncology and 2 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 1.08 beat Cardiff Oncology's score of -0.37 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cardiff Oncology Neutral
Qualigen Therapeutics Positive

Cardiff Oncology presently has a consensus target price of $10.10, suggesting a potential upside of 510.27%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Cardiff Oncology is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cardiff Oncology has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Summary

Cardiff Oncology beats Qualigen Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Turn Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Turn Therapeutics had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for Turn Therapeutics and 2 mentions for Qualigen Therapeutics. Turn Therapeutics' average media sentiment score of 1.47 beat Qualigen Therapeutics' score of 1.08 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Qualigen Therapeutics Positive
Turn Therapeutics Positive

Turn Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 102.58%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Turn Therapeutics is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Turn Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Turn Therapeutics' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A -771.52% -79.52%
Turn Therapeutics N/A N/A N/A

Turn Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$16.97M-$7.50N/A
Turn TherapeuticsN/AN/A-$3.19M-$0.16N/A

Summary

Turn Therapeutics beats Qualigen Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Cypherpunk Technologies?

Qualigen Therapeutics (NASDAQ:AIXC) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$16.97M-$7.50N/A
Cypherpunk TechnologiesN/AN/A$4.82M$0.0716.14

Qualigen Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

In the previous week, Cypherpunk Technologies had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for Cypherpunk Technologies and 2 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 1.08 beat Cypherpunk Technologies' score of -0.28 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Qualigen Therapeutics Positive
Cypherpunk Technologies Neutral

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cypherpunk Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Cypherpunk Technologies' return on equity of -99.76% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A -771.52% -79.52%
Cypherpunk Technologies N/A -99.76%-79.44%

Summary

Cypherpunk Technologies beats Qualigen Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Cognition Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$16.97M-$7.50N/A
Cognition TherapeuticsN/AN/A-$23.49M-$0.24N/A

Qualigen Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

In the previous week, Cognition Therapeutics had 7 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 9 mentions for Cognition Therapeutics and 2 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 1.08 beat Cognition Therapeutics' score of 0.50 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Qualigen Therapeutics Positive
Cognition Therapeutics Positive

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cognition Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 188.60%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cognition Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Cognition Therapeutics' return on equity of -72.68% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A -771.52% -79.52%
Cognition Therapeutics N/A -72.68%-53.07%

Summary

Cognition Therapeutics beats Qualigen Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Oncolytics Biotech?

Qualigen Therapeutics (NASDAQ:AIXC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Oncolytics Biotech had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for Oncolytics Biotech and 2 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 1.08 beat Oncolytics Biotech's score of -0.37 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Qualigen Therapeutics Positive
Oncolytics Biotech Neutral

Qualigen Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Oncolytics Biotech has a consensus price target of $8.50, suggesting a potential upside of 892.99%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Oncolytics Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$16.97M-$7.50N/A
Oncolytics BiotechN/AN/A-$28.76M-$0.29N/A

Qualigen Therapeutics' return on equity of -771.52% beat Oncolytics Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A -771.52% -79.52%
Oncolytics Biotech N/A -2,185.97%-243.94%

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Oncolytics Biotech beats Qualigen Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AIXC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AIXC vs. The Competition

Export
MetricQualigen TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$26.43M$923.92M$4.19B$12.32B
Dividend YieldN/A4.84%6.42%5.35%
P/E Ratio-0.171.4522.7125.37
Price / SalesN/A117.25156.1773.28
Price / CashN/A20.0753.4656.33
Price / Book1.618.3439.096.93
Net Income-$16.97M-$3.77M$113.55M$333.88M
7 Day Performance-4.74%9.39%2.97%0.33%
1 Month Performance5.24%60.76%4.88%2.11%
1 Year PerformanceN/A114.56%16.68%33.31%

Qualigen Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AIXC
Qualigen Therapeutics
0.5383 of 5 stars		$1.31
-3.3%		N/AN/A$26.43MN/AN/A50
CRDF
Cardiff Oncology
1.4295 of 5 stars		$1.68
+4.0%		$10.10
+503.0%		-35.2%$114.52M$590KN/A20
TTRX
Turn Therapeutics
3.3645 of 5 stars		$3.80
+2.6%		$8.00
+110.8%		N/A$113.05MN/AN/A2
CYPH
Cypherpunk Technologies
0.9455 of 5 stars		$1.15
+7.5%		N/A+193.4%$112.32MN/A16.4340
CGTX
Cognition Therapeutics
3.1646 of 5 stars		$1.24
-0.4%		$3.33
+169.9%		+259.8%$110.35MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AIXC) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel